Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, Korea.
APMIS. 2013 Feb;121(2):95-104. doi: 10.1111/j.1600-0463.2012.02942.x. Epub 2012 Aug 17.
We evaluated growth factors/receptors expression in gastric adenocarcinoma. Immunohistochemistry was used to evaluate epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), VEGF-D, VEGF receptor (VEGFR)-2, VEGFR-3, transforming growth factor (TGF)-α, TGF-β1, and TGF-β-RII in tissue microarrays of adenocarcinoma, dysplasia, metaplasia, and gastritis. In adenocarcinoma, the expression rates of EGFR, VEGF, VEGF-D, VEGFR-2, VEGFR-3, TGF-α, TGF-β1, and TGF-β-RII were 2.0%, 0%, 10.7%, 4.4%, 11.2%, 26.3%, 9.4%, and 19.5%, respectively. VEGF-D, TGF-α, TGF-β1, and TGF-β-RII expression rate were higher in adenocarcinoma than in other groups. TGF-β-RII expression was correlated with VEGFR-3, VEGF-D, and TGF-α expression in adenocarcinomas. Tumor location, histologic type, stage, lymphatic invasion, perineural invasion, angioinvasion, VEGF-D, and VEGFR-2 expressions were associated with patient survival in a log rank test and advanced stage and positive expression of VEGF-D were poor prognostic factors using Cox analysis. VEGF-D expression may be of prognostic value in gastric adenocarcinoma, whereas EGFR and TGF family expression may only have a minor influence.
我们评估了胃腺癌中生长因子/受体的表达。免疫组织化学用于评估表皮生长因子受体（EGFR）、血管内皮生长因子（VEGF）、VEGF-D、VEGF 受体（VEGFR）-2、VEGFR-3、转化生长因子（TGF）-α、TGF-β1 和 TGF-β-RII 在腺癌、异型增生、化生和胃炎的组织微阵列中的表达。在腺癌中，EGFR、VEGF、VEGF-D、VEGFR-2、VEGFR-3、TGF-α、TGF-β1 和 TGF-β-RII 的表达率分别为 2.0%、0%、10.7%、4.4%、11.2%、26.3%、9.4%和 19.5%。与其他组相比，VEGF-D、TGF-α、TGF-β1 和 TGF-β-RII 的表达率在腺癌中更高。TGF-β-RII 的表达与腺癌中 VEGFR-3、VEGF-D 和 TGF-α 的表达相关。肿瘤位置、组织学类型、分期、淋巴浸润、神经周围浸润、血管浸润、VEGF-D 和 VEGFR-2 的表达在对数秩检验中与患者生存相关，Cox 分析显示晚期和 VEGF-D 阳性表达是不良预后因素。VEGF-D 表达可能对胃腺癌具有预后价值，而 EGFR 和 TGF 家族表达可能仅具有较小的影响。
